| Bioactivity | FSG67 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor with an IC50 of 24 μM[1]. | ||||||||||||
| Target | GPAT | ||||||||||||
| Invitro | FSG67 reduces GSK3β phosphorylation and signaling after acetaminophen overdose[1].FSG67 results in a dose-dependent increase in oxidative metabolism in mature adipocytes with an IC50 of 27.7 ± 4.4 μM[2]. | ||||||||||||
| Name | FSG67 | ||||||||||||
| CAS | 1158383-34-6 | ||||||||||||
| Formula | C16H25NO4S | ||||||||||||
| Molar Mass | 327.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Clemens MM, et al. The inhibitor of glycerol 3-phosphate acyltransferase FSG67 blunts liver regeneration after acetaminophen overdose by altering GSK3β and Wnt/β-catenin signaling. Food Chem Toxicol. 2019 Mar;125:279-288. [2]. Reilly SM, et al. Catecholamines suppress fatty acid re-esterification and increase oxidation in white adipocytes via STAT3. Nat Metab. 2020 Jul;2(7):620-634. |